Search results
Results from the WOW.Com Content Network
A new therapy for metastatic melanoma was shown to be more effective than a leading immunotherapy for the skin cancer. Skip to main content. 24/7 Help. For premium support please call: 800-290 ...
IL-2 was the first new therapy approved (1990 EU, 1992 US) for the treatment of metastatic melanoma in 20 years. [139] IL-2 may offer the possibility of a complete and long-lasting remission in this disease in a small percentage of people with melanoma. [ 140 ]
Phase III clinical trials include treatment of esophageal cancer, [15] urothelial carcinoma, [16] metastatic head and neck cancer, [17] and liver metastasis in colorectal cancer. [18] Early trials showed limited efficacy in patients with malignant melanoma, bladder cancer, prostate cancer, and renal cell carcinoma. [11]
A liver metastasis is a malignant tumor in the liver that has spread from another organ that is affected by cancer. The liver is a common site for metastatic disease because of its rich, dual blood supply (the liver receives blood via the hepatic artery and portal vein). Metastatic tumors in the liver are 20 times more common than primary liver ...
A huge advancement in cancer treatment after the Food and Drug Administration just approved a type of cell therapy for patients with late-stage melanoma.
A phase III trial (vs dacarbazine) in patients with previously untreated metastatic melanoma showed an improved rates of overall and progression-free survival. [18] In June 2011, positive results were reported from the phase III BRIM3 BRAF-mutation melanoma study. [19] The BRIM3 trial reported good updated results in 2012. [20]
As of 2019, pembrolizumab, which blocks PD-1, programmed cell death protein 1, has been used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a second-line treatment for head and neck squamous cell carcinoma (HNSCC), after platinum-based chemotherapy ...
Renal cell cancer and melanoma are generally considered to be radioresistant but radiation therapy is still a palliative option for many patients with metastatic melanoma. Combining radiation therapy with immunotherapy is an active area of investigation and has shown some promise for melanoma and other cancers.